Omics analysis of HIV during synthetic opioid exposure

NIH RePORTER · NIH · R61 · $150,215 · view on reporter.nih.gov ↗

Abstract

Abstract In December 2019, an outbreak of pneumonia of unknown cause occurred in Wuhan, China, and the causative agent was identified as a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Additionally, the US is in the midst of a major opioid epidemic largely attributed to synthetic opioids such as fentanyl, and the SARS-CoV-2 pandemic is occurring in parts of the world where recent increases in HIV due to the opioid crisis have been reported. With the SARS-CoV-2 pandemic, there are major concerns about worsening of the opioid crisis. People suffering from addiction are particularly vulnerable to increased infection with SARS-CoV-2 and more advanced disease severity. Many opioids are also associated with immune suppression and enhanced viral pathogenesis. Thus, foundational research on virus-virus and virus-opioid interactions is essential for understanding the impact of SARS-CoV-2 on other co- morbid conditions and for developing robust therapeutic options for limiting viral infection and pathogenesis in high-risk populations.

Key facts

NIH application ID
10158901
Project number
3R61DA048439-02S1
Recipient
UNIVERSITY OF CINCINNATI
Principal Investigator
JASON T BLACKARD
Activity code
R61
Funding institute
NIH
Fiscal year
2020
Award amount
$150,215
Award type
3
Project period
2019-03-01 → 2021-12-31